Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05714371 · ClinicalTrials.gov registry record
Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 618
- Enrollment target
NCT05714371: Completed study, sponsored by Novartis Pharmaceuticals.
NCT05714371 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 618 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05714371 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 618 participants
- Enrollment target
Study Summary
This was a retrospective cohort study using the PharMetrics database. The analysis was conducted using the most recent 5 years of data from the database, January 1, 2015, to October 30, 2020. Included patients were followed for outcome evaluation from the index date (first prescription of treatment, immunotherapy \[IO\], or targeted therapy \[TT\] following diagnosis of non-metastatic malignant melanoma and evidence of first lymph node resection), until the first occurrence or end of continuous eligibility or end of the study period.
Interventions
- DRUG Pembrolizumab
- DRUG Nivolumab
- DRUG Ipilimumab + nivolumab
- DRUG Dabrafenib + trametinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 618 participants |
| Start Date | 2021-10-02 |
| Est. Completion | 2022-01-27 |
What the finished NCT05714371 record still lists
NCT05714371 is an observational study that tracks outcomes without assigning an intervention. The registered 618 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT05714371 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05714371 about?
NCT05714371 is a clinical study titled "Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma". This was a retrospective cohort study using the PharMetrics database. The analysis was conducted using the most recent 5 years of data from the database, January 1, 2015, to October 30, 2020. Included patients were followed for outcome evaluation from the index date (first prescription of treatment,...
What is the current status of trial NCT05714371?
This trial is currently completed. The enrollment target is 618 participants. The study started on 2021-10-02. Estimated completion is 2022-01-27.
What interventions are being tested in trial NCT05714371?
The interventions under investigation include: Pembrolizumab (DRUG), Nivolumab (DRUG), Ipilimumab + nivolumab (DRUG), Dabrafenib + trametinib (DRUG).
Who is sponsoring clinical trial NCT05714371?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05672927 · 618 participants · Phase 4
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
- NCT06220721 · 618 participants · NA
Reducing the Risk of Chronic Hypertension and Improving Vascular Function Following Preeclampsia
- NCT02610179 · 617 participants · NA
Strawberry Candy Twists as an Alternative Screen for Gestational Diabetes: A Prospective Trial
- NCT02282969 · 620 participants
PCORI-CER-1306-03385 Lung Cancer Screening Decision Aid Development and Testing
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI